Clinical Trials Browser

Phase 1/2 × Lung Neoplasms × rilotumumab × Clear all

NCT00791154 2024-08-23

SCLC

Phase 1/2 Terminated

213 enrolled 16 charts

Lung Neoplasms, Pleural Effusion, Malignant, Small Cell Lung Carcinoma